Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market opportunitiesDr. Sabine ...
From my colleague Allison DeAngelis: A new cancer treatment developed by ITM Isotope Technologies Munich SE has succeeded in a Phase 3 trial, setting the stage for a competitor to Novartis ...
Siemens Aktiengesellschaft (XETRA:SIE.DE), headquartered in Munich, Germany ... dividend stocks to consider for an income portfolio. Novartis AG (NYSE:NVS) is a Swiss global healthcare giant ...
Kunz declared ties with Ipsen, Novartis, Genentech/Roche, Amgen, Crinetics Pharmaceuticals, Natera, HUTCHMED, and ITM Isotope Technologies Munich SE. Gralow declared consulting or advisory roles ...
For example, genomic services and solutions firm Novogene is using PacBio’s Revio long-read sequencing system to expand the genomic research abilities of its Munich, Germany-based lab.
ITM, which is short for Isotope Technologies Munich, plans to present full trial data at an ... an approved radiopharmaceutical sold by Novartis. In an interview last June, former ITM CEO Steffen ...
For instance, Novartis’ $1 billion acquisition of Massachusetts-based ... These are areas in which ITM has been leading for 20 years: we have two manufacturing sites in the Munich area and are the ...
Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
Novartis NOVN0.30%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback